GPIb␣ binding to von Willebrand factor (VWF) exposed at a site of vascular injury is thought to be the first step in the formation of a hemostatic plug. However, our previous studies in VWF-deficient mice demonstrated delayed but not absent arterial thrombus formation, suggesting that, under these conditions, GPIb␣ may bind other ligands or that a receptor other than GPIb␣ can mediate platelet adhesion. Here, we studied thrombus formation in transgenic mice expressing GPIb␣ in which the extracellular domain was replaced by that of the human IL-4 receptor (IL4R␣͞GPIb␣-tg mice). Platelet adhesion to ferric chloride-treated mesenteric arterioles in IL4R␣͞GPIb␣-tg mice was virtually absent in contrast to avid adhesion in WT mice. As a consequence, arterial thrombus formation was inhibited completely in the mutant mice. Our studies further show that, when infused into WT recipient mice, IL4R␣͞ GPIb␣-tg platelets or WT platelets lacking the 45-kDa N-terminal domain of GPIb␣ failed to incorporate into growing arterial thrombi, even if the platelets were activated before infusion. Surprisingly, platelets lacking ␤3 integrins, which are unable to form thrombi on their own, incorporated efficiently into WT thrombi. Our studies provide in vivo evidence that GPIb␣ absolutely is required for recruitment of platelets to both exposed subendothelium and thrombi under arterial flow conditions. Thus, GPIb␣ contributes to arterial thrombosis by important adhesion mechanisms independent of the binding to VWF.
P
latelet adhesion to the extracellular matrix (ECM) is a key step in thrombus formation as found in hemostasis and thrombosis. The interaction of platelet receptor GPIb␣ and von Willebrand factor (VWF) exposed in the ECM is commonly accepted as the key event required for the initial tethering of platelets along the damaged vascular wall, especially under conditions of high shear stress (1) (2) (3) . Most of the data supporting this model are derived from in vitro studies in flow chamber models, where whole blood or isolated platelets are perfused under physiological flow conditions over adhesive surfaces such as collagen or VWF. Using mice deficient in VWF (4), we previously evaluated the role of VWF in ferric chloride-induced thrombosis in mesenteric arterioles (5) . Compared with controls, the number of VWF Ϫ/Ϫ platelets tethering along the injured vessel wall was initially reduced by Ϸ80%, causing a delay of several minutes in thrombus formation. However, VWF Ϫ/Ϫ mice managed to form stable thrombi, which in Ϸ50% of cases led to complete occlusion of the injured arteriole (5) . In many mice, a high-shear channel formed that persisted for Ͼ25 min. The presence of such channels also was reported for hemostatic plugs in pigs with von Willebrand's disease (6) . These data suggested that a ligand for GPIb␣ other than VWF was expressed in the vessel wall, or that a receptor other than GPIb␣-mediated platelet adhesion in injured arterioles of VWF Ϫ/Ϫ mice.
The GPIb-V-IX receptor complex consists of four gene products, GPIb␣, GPIb␤, GPIX, and GPV (2, 7, 8) . Approximately 25,000 copies of GPIb-IX and 12,000 copies of GPV are expressed on resting platelets. The ligand-binding site for VWF is located within the 45-kDa N-terminal region of GPIb␣. Recent studies demonstrated that the GPIb-V-IX complex plays a broader role in vascular biology, because it also mediates the interaction of resting platelets with activated leukocytes through its binding to Mac-1 (9, 10) and activated endothelial cells through its binding to P-selectin (11) . Furthermore, GPIb␣ interacts with thrombin (12, 13) , high molecular weight kininogen (14) , coagulation factors XI and XII (15, 16) , and TSP-1 (17) . Upon ligand binding, the GPIb-V-IX receptor complex can induce signals leading to calcium mobilization, the rearrangement of the cytoskeleton, granule release, and activation of ␣IIb␤3 integrin (18, 19) .
The importance of the GPIb-V-IX receptor for hemostasis is shown by the strong bleeding diathesis found in Bernard-Soulier syndrome (BSS) patients lacking the GPIb-V-IX complex on the platelet surface or in patients lacking VWF (1, 20) . A similar bleeding phenotype was reported for mice deficient in GPIb␣ (21) . However, additional characteristics of BSS, such as marked thrombocytopenia and giant platelets, are also found in GPIb␣ Ϫ/Ϫ mice, making it difficult to specifically address the role of GPIb␣ in thrombosis.
Therefore, we decided to evaluate thrombosis in mice expressing GPIb␣, in which most of the extracellular domain has been replaced by the ␣-subunit of the human IL-4 receptor (IL4R␣) (22) . Mice transgenic for this chimeric receptor (IL4R␣͞GPIb␣-tg) on the GPIb␣ Ϫ/Ϫ background are characterized by normal platelet size and a platelet count of Ϸ65-70% of WT mice. Like complete GPIb␣ deficiency, lack of the extracellular domain of GPIb␣ results in a severe bleeding phenotype (22) .
We demonstrate here that platelet adhesion to the exposed extracellular matrix is completely inhibited in arterioles of IL4R␣͞GPIb␣-transgenic mice. The comparison with the milder phenotype of VWF Ϫ/Ϫ animals strongly suggests the existence of a ligand other than VWF for GPIb␣ in the injured vessel. Furthermore, our studies show that surface expression of GPIb␣, but not ␤3 integrin, on circulating platelets is crucial for their recruitment into arterial thrombi. modification, which could result in altered surface expression of important platelet adhesion receptors. As shown in Fig. 1A , no significant differences could be observed between WT and IL4R␣͞GPIb␣-tg platelets with regard to the surface expression of integrins ␣2␤1 and ␣IIb␤3, or GPVI. Staining for both GPV and GPIX, members of the Ib-V-IX complex, also showed no significant difference between WT and IL4R␣͞GPIb␣-tg platelets, whereas staining for GPIb␣ was observed on WT but not IL4R␣͞GPIb␣-tg platelets. In addition to the expression level of surface adhesion receptors, we studied ␣IIb␤3 integrin activation and calcium flux in WT and IL4R␣͞GPIb␣-tg platelets stimulated with various agonists. These studies are important because they provide information on the function of surface-expressed agonist receptors, intracellular signaling pathways, and the major platelet integrin responsible for platelet adhesion and aggregation. No significant shift in the dose-response to ADP (in the presence of 5 M concentration of the thromboxane A2 mimetic U46619) or thrombin was observed in flow cytometry studies aimed to directly measure ␣IIb␤3 activation. Interestingly, at all agonist concentrations tested, binding of probes detecting the activated form of ␣IIb␤3 such as the monoclonal antibody JON͞A-PE (Fig. 1B) or antibodies detecting surface-bound fibrinogen (data not shown) was significantly stronger on IL4R␣͞GPIb␣-tg platelets when compared with WT platelets. In addition, no significant differences in calcium flux were observed between WT and mutant platelets stimulated with ADP, U46619, or thrombin (data not shown). The ability of ␣IIb␤3 to bind ligands and mediate platelet aggregation was tested further in standard aggregometry, where no differences between WT and IL4R␣͞ GPIb␣-tg platelets were found (Fig. 1C) .
Impaired Arterial Thrombosis in IL4R␣͞GPIb␣-tg Mice. To visualize the adhesive function of IL4R␣͞GPIb␣-tg platelets in vivo, we performed intravital microscopy studies in a model of arterial thrombosis. In this model, platelets from a donor mouse are isolated, washed, labeled with calcein-AM, and infused into a recipient mouse of the same genetic background. Shortly after visualization of a mesenteric arteriole, the vessel wall was injured by application of ferric chloride (FeCl 3 ), and the adhesion of labeled platelets and the formation of thrombi at the site of injury was observed. The numbers of fluorescently labeled platelets deposited on vessel walls between 3-5 min after injury were counted over a 400-m length of vessel. Whereas strong tethering of platelets to the injured vessel wall was observed in WT mice 3-5 min after application of FeCl 3 (192.0 Ϯ 17.6 platelets per min), tethering of platelets was virtually absent (3.1 Ϯ 1.1 platelets per min) in IL4R␣͞GPIb␣-tg mice (P Ͻ 0.0001). Consequently, thrombus formation in arterioles of IL4R␣͞GPIb␣-tg mice was completely absent throughout the 40-min course of the experiment, whereas vessel occlusion in WT mice was reached 15.9 Ϯ 2 min after application of FeCl 3 (Fig. 2) . Thus, GPIb␣ plays an essential role in the initial platelet adhesion that leads to arterial thrombosis. In this model, we propose to study which surface receptors are needed for platelet adhesion to a thrombus whose formation is driven by WT platelets. To test whether IL4R␣͞GPIb␣-tg platelets also are defective in their adhesion to an already existing thrombus, we infused WT mice with WT platelets labeled with calcein-green together with IL4R␣͞GPIb␣-tg platelets labeled with calceinred͞orange (or vice versa) to reach a total of 2% labeled platelets for both genotypes. Whereas labeled WT platelets showed normal adhesion to the damaged vascular wall and strong incorporation into the growing thrombus, the adhesion of labeled IL4R␣͞GPIb␣-tg platelets to the ECM and to the growing thrombi was strongly impaired (Fig. 3) . To compare the incorporation into a growing thrombus of WT and IL4R␣͞GPIb␣-tg platelets, two independent observers assigned a score from 0 to 10 for IL4R␣͞GPIb␣-tg platelets, with ''0'' representing ''no incorporation'' and ''10'' representing ''incorporation efficiency of WT platelets.'' IL4R␣͞GPIb␣-tg platelets showed significantly less incorporation than WT platelets (score ϭ 0.9 Ϯ 0.5; P ϭ 0.001; n ϭ 5).
A similar defect was observed when we studied the adhesive function of WT platelets lacking the 45-kDa N-terminal region of GPIb␣ (WT-45-kDa platelets), generated by treatment with O-sialoglycoprotein endopeptidase for 30 min in vitro (23) . The efficiency of GPIb␣ cleavage was verified by flow cytometry with antibodies directed against epitopes located within and outside the 45-kDa N-terminal domain of GPIb␣ (Fig. 4A ). Similar to IL4R␣͞GPIb␣-tg platelets, tethering of WT-45-kDa platelets was almost completely absent (4.0 Ϯ 2.8 platelets per min compared with 178 Ϯ 23 platelets per min for WT; P Ͻ 0.002), and so was their incorporation into a growing WT thrombus (Fig.  4B) . Together, these data indicate that platelets lacking the N-terminal ligand-binding domain on GPIb␣ are incapable of incorporating into a growing WT thrombus under arterial flow conditions.
To rule out that impaired platelet activation in response to thrombin or other agonists is responsible for the adhesion defect of IL4R␣͞GPIb␣-tg platelets, we studied the incorporation of thrombin-activated platelets into WT thrombi. It was shown that thrombin-activated platelets are not cleared upon infusion into mice (24, 25) . Platelet activation was confirmed by examining P-selectin expression before infusion (data not shown). The preactivation of IL4R␣͞GPIb␣-tg platelets did not stimulate their adhesion to either ECM or thrombi (Fig. 4C ).
␤3 Integrin-Deficient Platelets Incorporate into Growing WT Thrombi in a GPIb␣-Dependent Manner. Because platelet recruitment to thrombi strongly depended on the expression of GPIb␣, we wondered whether platelets lacking integrin ␣IIb␤3, the key receptor mediating platelet aggregation (26) , are capable of incorporating into a growing WT thrombus. To our surprise, we observed effective incorporation of ␤3 Ϫ/Ϫ platelets into WT thrombi, both in the early phase of thrombus growth and at the time of occlusion (Fig. 5A) . In contrast to IL4R␣͞GPIb␣-tg platelets, the incorporation of ␤3 Ϫ/Ϫ platelets was not significantly different from that of WT platelets (incorporation score ϭ 9.25 Ϯ 0.75; P ϭ 0.5). However, treatment with O-sialoglycoprotein endopeptidase to remove the 45-kDa Nterminal domain of GPIb␣ abolished the incorporation of ␤3 Ϫ/Ϫ platelets (Fig. 5B) , suggesting that GPIb␣, but not ␣IIb␤3, is the main receptor facilitating platelet recruitment and adhesion to thrombi under arterial flow conditions.
Discussion
Here we show that the lack of the extracellular domain of GPIb␣ abolishes platelet adhesion to sites of vascular damage in injured arterioles (Fig. 2) . This defect in platelet adhesion is the strongest that our group has observed so far by using this model in genetically modified mice. The phenotype is even more severe than that of mice deficient in integrin ␣IIb␤3, the major integrin mediating platelet aggregation, which show significant platelet tethering but fail to form arterial thrombi (27-29) (Richard O. Hynes, personal communication). In addition to their inability to adhere to the exposed ECM, IL4R␣͞GPIb␣-tg platelets or platelets lacking the 45-kDa N-terminal domain of GPIb␣ infused into WT mice were unable to incorporate into growing WT thrombi (Figs. 3 and 4) . This finding is consistent with two previous reports demonstrating in vitro that the GPIb-VWF interaction plays a key role in platelet thrombus growth, i.e., the adhesion of platelets to already adherent platelets (30, 31) . However, our findings provide important insights into the mechanism(s) underlying platelet-platelet cohesion, because we were able to demonstrate that the incorporation of mutant platelets into a growing WT thrombus in arterioles does not require the major platelet integrin, ␣IIb␤3 (Fig. 5A ). This finding is surprising given that the absence of functional ␣IIb␤3, either due to the addition of function-blocking compounds or genetic deficiency, leads to complete inhibition of thrombus formation under conditions of arterial flow (26-28, 32) (Richard O. Hynes, personal communication). We do not understand how ␤3 integrin-deficient platelets manage to firmly adhere to WT platelets, but we could demonstrate that their recruitment requires the extracellular domain of GPIb␣ (Fig. 5B) . One possibility would be that GPIb␣ facilitates the tethering of ␤3 Ϫ/Ϫ platelets, mediated by a GPIb␣ ligand such as VWF, which could cross-link the incoming platelet to another GPIb␣ or to an integrin, such as ␣IIb␤3 on the thrombus surface. Firm adhesion of newly recruited platelets then may be mediated by activated ␤1 integrins such as ␣5␤1 (fibronectin receptor). Fibronectins are present not only in the ECM but are also found in plasma and platelets (33) . This idea might be supported by our recent findings showing that the lack of plasma fibronectin or even a reduction in its levels leads to significantly prolonged occlusion time in injured arterioles in mice because of the constant shedding of platelets from the forming thrombus (34, 35) . Alternatively, an integrin-independent adhesion process could direct platelet incorporation into the WT thrombus, possibly entirely dependent on the interaction of GPIb␣ with one (or more) of its ligands. Interestingly, while this paper was under review, Ruggeri et al. (36) reported that platelet aggregation under very high arterial shear conditions in vitro requires GPIb␣ and VWF, but is independent of platelet activation (and, therefore, integrin ␣IIb␤3). Thus, there is growing evidence that GPIb␣ can mediate firm adhesion of nonactivated platelets independent of the engagement of ␣IIb␤3.
It has been demonstrated that integrin cytoplasmic domains expressed as transgenic chimeric proteins can behave as inhibitors of endogenous integrin activation. For example, their cytoplasmic domains can act as a ''sink'' for intracellular signaling molecules, which are limited in quantities (37) (38) (39) . One could imagine that, similarly, the expression of the IL4R␣͞GPIb␣ chimeric protein could negatively affect platelet signaling͞ function. However, this hypothesis provides an unlikely explanation for the adhesion defect observed in IL4R␣͞GPIb␣-tg platelets, because we can recapitulate the adhesion deficit in WT platelets by the enzymatic removal of the 45-kDa N-terminal domain of GPIb␣ (Fig. 4) . Furthermore, IL4R͞GPIb␣-tg platelets showed normal calcium flux and ␣IIb␤3 activation when activated with various physiological platelet agonists (Fig. 1) . In fact, we observed increased binding of probes detecting the activated form of ␣IIb␤3 on stimulated IL4R͞GPIb␣-tg platelets (Fig. 1B) . Most likely, the better access of such probes is explained by the absence of the heavily glycosylated GPIb␣ extracellular domain. In any case, we were unable to detect any defect in the activation of IL4R␣͞GPIb␣-tg platelets.
The best known ligand for GPIb␣ is VWF. Interestingly, the phenotype of mice lacking the extracellular domain of GPIb␣ is far more severe than that of mice deficient in VWF. Examined in the same model of arteriolar injury, the number of VWF Ϫ/Ϫ platelets tethering along the injured vessel wall is Ϸ20% of WT, whereas we observed Ͻ2% of WT in the IL4R␣͞GPIb␣-tg mice. The reduced but not absent platelet adhesion observed in VWF Ϫ/Ϫ mice causes a delay of several minutes in thrombus formation. However, unlike IL4R␣͞GPIb␣-tg mice, the VWF Ϫ/Ϫ mice manage to form stable thrombi, which in Ϸ50% of cases lead to complete occlusion of the injured arteriole (5). The strikingly stronger antithrombotic phenotype of IL4R␣͞ GPIb␣-tg mice compared with VWF Ϫ/Ϫ mice is surprising for several reasons. First, VWF has been established in previous studies as the major ligand for GPIb␣, at least with regard to platelet adhesion to a thrombogenic surface under conditions of high shear stress (3, 40) . Second, VWF is also a prominent ligand for the major platelet integrin, ␣IIb␤3. The interaction of ␣IIb␤3 with VWF has been shown to be an important step in platelet adhesion and thrombus formation, both in vitro and in vivo (3, 41, 42) . Finally, VWF is a carrier protein for factor VIII (FVIII), a plasma clotting factor important for the generation of thrombin at sites of vascular damage. In human and mouse type 1 von Willebrand disease, markedly reduced VWF levels lead to a decrease in the plasma concentration of FVIII as a result of the lack of protection against proteolysis provided by VWF (4, (43) (44) (45) . Thus, one might have expected a similar or stronger antithrombotic phenotype in VWF Ϫ/Ϫ mice compared with mice lacking the extracellular domain of GPIb␣.
The strong adhesion defect of IL4R␣͞GPIb␣-tg platelets observed in injured arterioles shows that (i) other receptors such as the collagen receptor GPVI (46) cannot support platelet adhesion in the absence of GPIb␣, and (ii) a ligand(s) other than VWF can support GPIb␣-dependent platelet adhesion. Thrombospondin-1 (TSP-1) is one likely candidate, because it is has been identified as an alternative ligand to VWF, allowing for GPIb-dependent platelet adhesion at high-shear conditions in vitro (17) . However, TSP-1 also has been shown to affect thrombosis by protecting (sub)endothelial VWF from cleavage by ADAMTS13 (47), a mechanism unrelated to its role as a ligand for GPIb␣. P-selectin, an adhesion receptor found on activated platelets and endothelial cells, is also a ligand for GPIb␣ (11) . Vascular injury by FeCl 3 , however, leads to rapid endothelial denudation (5), making it unlikely that the Pselectin-GPIb␣ interaction plays a role in platelet adhesion to the vessel wall, even in the absence of VWF. P-selectin, on the other hand, could play a role in platelet adhesion to thrombi, and defects in thrombus growth were shown in the presence of anti-P-selectin antibodies (48) . Further studies in mice with combined mutations in VWF and TSP-1 or VWF and P-selectin are needed to clarify this question.
In summary, we have shown that GPIb␣ is absolutely required for platelet adhesion͞thrombus formation under high-shear conditions as found in mesenteric arterioles. Because platelets and platelet adhesion also contribute to various other pathophysiological processes including inflammation, heart disease, and angiogenesis (49) (50) (51) , inhibitors of GPIb␣ that interfere with platelet adhesion might become powerful drugs in the future.
Materials and Methods
Animals. IL4R␣͞GPIb␣ transgenic (22) , ␤3-deficient (27), and the respective control mice were bred and housed in our facilities. Experimental procedures were approved by the Animal Care and Use Committee of the CBR Institute for Biomedical Research.
Reagents and Antibodies. The following reagents were used: Lovenox (enoxaparin sodium) (Aventis Pharmaceuticals Products, Sanofi-Aventis, Bridgewater, NJ), heparin-coated microcapillaries (VWR Scientific, West Chester, PA), collagen reagent Horm (NYCOMED, Munich, Germany), BSA (Chrono-log Corp., Haverton, PA), prostacyclin (PGI 2 ), thromboxane A 2 mimetic U46619, human thrombin, ADP, and ferric chloride (FeCl 3 ) (all from Sigma, St. Louis, MO), Osialoglycoprotein endopeptidase (Cedarlane, Hornby, ON, Canada), Fluo-3, calcein AM (calcein-green), and calcein red-orange AM (all from Molecular Probes, Eugene, OR). Monoclonal antibodies against human IL4R␣, mouse CD62P, and mouse ␣2␤1 were from BD Pharmingen, San Diego, CA. Antibodies against mouse receptors ␣IIb␤3, GPVI, GPV, GPIX, and GPIb␣ were from emfret Analytics (Wuerzburg, Germany).
Flow Cytometry. Expression of adhesion receptors on resting platelets.
Mice were bled from the retro-orbital plexus under isoflurane anesthesia (IsoFlo; Abbott Laboratories, Abbott Park, IL). Blood (7 volumes) was collected into a tube containing 30 units͞ml heparin in PBS (pH 7.4, 3 volumes) and diluted with modified Tyrode-Hepes buffer (137 mmol/liter NaCl͞0.3 mmol/ liter Na 2 HPO 4 ͞2 mmol/liter KCl͞12 mmol/liter NaHCO 3 ͞5 mmol/liter Hepes͞5 mmol/liter glucose, pH 7.3) containing 0.35% BSA. Platelets (2 ϫ 10 6 ) in diluted whole blood were incubated with saturating amounts of the indicated FITClabeled antibodies for 20 min at room temperature (RT) and analyzed immediately on a FACScalibur (Becton Dickinson, Rockville, MD). Expression of activated ␣IIb␤3 on stimulated platelets. Platelet-rich plasma was obtained from heparinized whole blood by centrifugation at 300 ϫ g for 10 min. Platelet-rich plasma was centrifuged at 1,000 ϫ g in the presence of PGI 2 (0.1 g͞ml) for 7 min at RT. After two washing steps, pelleted platelets were resuspended in modified Tyrode-Hepes buffer containing 0.35% BSA and 1 mM CaCl 2 . Platelets (2 ϫ 10 6 ) were activated with the indicated concentrations of thrombin or ADP (in the presence of 5 M U46619) for 10 min at RT, stained with PE-labeled antibodies against activated ␣IIb␤3 (JON͞A-PE (52), 10 min at RT), and immediately analyzed. Platelets were gated by forward scatter͞side scatter characteristics. Calcium flux. Washed platelets were incubated for 15 min with 5 M Fluo-3, stimulated with the indicated agonist concentrations, and immediately analyzed. Platelets were gated by forward scatter͞side scatter characteristics.
Treatment of Platelets with O-Sialoglycoprotein Endopetidase.
The N-terminal domain of GPIb␣ was removed from platelets as described in ref. 23 . Briefly, washed platelets (2 ϫ 10 9 ͞ml) were resuspended in modified Tyrode's buffer containing 1 mM CaCl 2 and incubated at 37°C for 30 min with 250 g͞ml Osialoglycoprotein endopeptidase. Aliquots of the platelet suspensions were analyzed by flow cytometry to detect alterations in GPIb␣ expression.
Aggregometry. Light transmission was measured by using platelet-rich plasma (ADP, collagen, U46619) or washed platelets (thrombin) adjusted to 3 ϫ 10 8 platelets per ml with modified Tyrode's buffer containing 1 mM CaCl 2 . Agonists were added at the indicated concentrations and transmission was recorded over 12 min on a Chrono-log 4-channel optical aggregation system (Chrono-log Corp.).
In Vivo Thrombosis Model. Platelets were labeled for 10 min with calcein-green (5 g͞ml) or calcein-red͞orange (2.5 g͞ml) and infused into 3-to 5-week-old anesthetized male mice. The mesentery was exposed through a midline abdominal incision. Vessels with a shear rate of 1,000-1,400 sec Ϫ1 were selected by using an Optical Doppler Velocimeter (Texas A&M University System Health Science Center, Cardiovascular Research Institute, College Station, TX). Arterioles were visualized with a Zeiss Axiovert 135-inverted microscope (Zeiss, Oberkochen, Germany) and adhesion of fluorescently labeled platelets was monitored in black and white with a silicon-intensified tube camera (C2400-08; Hamamatsu, Hamamatsu City, Japan) connected to an S-VHS video recorder (AG-6730; Panasonic, Matsushita Electric, Japan). Vessel injury was generated by using a filter paper (1 ϫ 4 mm) soaked with a 10% FeCl 3 solution and placed over the vessel for 5 min. The paper then was removed, and the vessel was covered with saline at 37°C. Vessels were monitored for 40 min after FeCl 3 treatment or until cessation of blood flow lasted Ͼ10 s (occlusion).
To determine platelet tethering to injured vessels, 10 l of FeCl 3 was superfused over mesenteric arterioles, and the number of fluorescently labeled platelets tethering to vessel walls was counted over a 400-m stretch of vessel.
For studies on the adhesion of activated platelets, calceinlabeled cells were treated with human thrombin (0.2 unit͞ml) for 5 min at 37°C in presence of 0.5 mM EDTA to avoid aggregation. Hirudin (1 unit͞ml) was added to stop the reaction. The activation was confirmed by surface expression of P-selectin. Platelets were infused intravenously so that they represented Ϸ2% of platelets in circulation.
In all experiments comparing the adhesion of two sets of platelets, the labeling with calcein-green and calcein-red͞orange was alternated between the two sets of platelets.
Statistical Analysis. Data are presented as mean Ϯ SEM. The differences in surface receptor expression, platelet adhesion, and thrombus formation were analyzed by unpaired, two-tailed Student's t test. The differences in platelet incorporation into growing thrombi were analyzed by Wilcoxon Signed Rank test. P values Ͻ0.05 were regarded as statistically significant.
Supporting Information. Movies show platelet adhesion͞thrombus formation in response to arteriolar injury in WT (Movie 1, which is published as supporting information on the PNAS web site) and IL4R␣͞GPIb␣ transgenic (Movie 2, which is published as supporting information on the PNAS web site) mice. The experimental detail is described in Fig. 2 legend. 
